President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the agreement, eligible patients will pay around $245 to $350 per month, the administration said.

Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.

Experimental pill versions of GLP-1 weight loss drugs by Novo Nordisk and Eli Lilly will receive FDA priority review. Read more here.

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure Pharmaceuticals to increase access to the weight-loss treatment in the nation.